TCGA-50-5049-01A-01R-1628-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 70
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.630
- INTERFERON_GAMMA_RESPONSE+0.560
- IL6_JAK_STAT3_SIGNALING+0.510
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
- INTERFERON_ALPHA_RESPONSE+0.500
- COMPLEMENT+0.460
- INFLAMMATORY_RESPONSE+0.460
- KRAS_SIGNALING_UP+0.350
- ANGIOGENESIS+0.310
- OXIDATIVE_PHOSPHORYLATION+0.300
Top 10 suppressed
- G2M_CHECKPOINT-0.350
- MYC_TARGETS_V2-0.330
- MITOTIC_SPINDLE-0.300
- E2F_TARGETS-0.290
- WNT_BETA_CATENIN_SIGNALING-0.240
- APICAL_SURFACE-0.140
- HEDGEHOG_SIGNALING-0.130
- KRAS_SIGNALING_DN-0.130
- GLYCOLYSIS-0.120
- SPERMATOGENESIS-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 6815eba1-06e5-46d6-ad4b-e4132b5d1638 | — | — | 0.890 |
| 2 | TCGA-50-5045-01A-01R-1628-07 | — | cohortA1 | 0.883 |
| 3 | 185b401a-bdc4-46b9-b2a5-7a66938f28f2 | — | — | 0.870 |
| 4 | TCGA-50-5055-01A-01R-1628-07 | — | cohortA1 | 0.869 |
| 5 | SRR8518419 | — | A | 0.864 |
| 6 | TCGA-44-3918-01A-01R-1107-07 | — | cohortA1 | 0.863 |
| 7 | TCGA-D8-A1Y2-01A-11R-A157-07 | — | C | 0.863 |
| 8 | TCGA-CQ-5325-01A-01R-1686-07 | — | — | 0.860 |
| 9 | TCGA-BH-A0EB-01A-11R-A034-07 | — | B | 0.858 |
| 10 | TCGA-XF-A9SX-01A-21R-A39I-07 | — | — | 0.855 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.630 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.560 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.510 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.500 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| COMPLEMENT | 0.460 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.460 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.350 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.310 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.290 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.280 | Idelalisib | — uncovered |
| APOPTOSIS | 0.270 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.220 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.210 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.180 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.170 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.140 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.120 | Inavolisib | — uncovered |